IGNT-IGEN Technologies, Inc News Out

[rob111]

Ingen Begins Ad Campaign and Branding of the New Oxyview Nasal Cannula
The Oxyview Nasal Cannula is Introduced to 170,000 Patients and Physicians This Fall

YUCAIPA, Calif., June 25, 2009 (GLOBE NEWSWIRE) -- Ingen Technologies, Inc. (Pink Sheets:IGNT) a leading Medical Device Manufacturer focused in the $8 Billion global Respiratory Markets for the growing ageing population and emerging markets for Home (DME), Hospital and Aviation Industries, announced today that the company has developed an advertising and branding campaign for the new Oxyview Nasal Cannula.

The company marketing staff is working with COPD Digest on various full color page ads and news articles in the next several editions. There are also scheduled articles with other major publications in the respiratory industry such as the well respected MedCo Forum. The company has chosen COPD Digest as their major source of advertising because COPD Digest, the first free, internationally distributed magazine on COPD, currently has a circulation of 170,000 individuals. Being one of the first programs created alongside the Foundation's establishment, the COPD Digest's purpose is to disseminate up-to-date information on research, latest therapies, legislative issues, and other useful information for individuals with COPD worldwide. The Digest was and is filling in a knowledge gap about COPD management that exists in both the patient and physician population.

The new Oxyview Nasal Cannula is available to the 23 million COPD home oxygen patients in the US and 600 million COPD home oxygen patients worldwide. The company is under ISO Certification training with the Emergo Consulting Group and has recently completed certification for training on June 10, 2009 for the ISO 13485:2003 Health Canada (CMDR) and FDA quality system requirements under 21 CFR, Part 820. The ISO certification allows the new Oxyview and Oxyview Nasal Cannula to be distributed and sold in China, Japan, Canada and Europe.

Projected annual sales potentials of the new Oxyview Nasal Cannula are $200M. "We are excited about the new ad saturation campaign of our Oxyview Nasal Cannula for the millions of COPD patients and physicians. These patients have been using 2-4 nasal cannulas a month during oxygen therapy. The therapy normally lasts the rest of their lives. The conventional style cannulas do not provide verification of oxygen flow rate, and the patients must rely on the equipment functionality. The new Oxyview Nasal Cannula provides the home oxygen patients with a quality nasal cannula and in-line oxygen flow meter that provides an accurate reading of oxygen flow rate and a tremendous amount of confidence for the patients and physicians," stated Scott R. Sand, Chief Executive Officer and Chairman of the Board.





About Oxyview:

Oxyview is a proprietary medical device with US issued patents that stands alone in an increasing patient home oxygen therapy market while there are 23 million patients diagnosed with chronic obstructive pulmonary disease (COPD) in the United States, according to the World Health Organization, and another 12 million patients that are undiagnosed in the US. COPD is the fifth leading cause of death in the US and there are 600 million COPD patients worldwide where in most cases, COPD is either the first or second leading cause of death in other countries. The majority of COPD patients require continued home oxygen therapy, which includes all of the required equipment supplied by the home (DME) provider. With the new regulations for oxygen reimbursement in the US, the home (DME) providers need to cut costs to stay in business. Oxyview provides a substantial savings as a result of decreasing the number of service calls for the home (DME) provider. Oxyview is a pneumatic metering device that displays oxygen flow near the patient. The Oxyview flow meter easily and quickly installs on to the oxygen tubing nearest the patient where oxygen flow matters the most. Without the Oxyview, patients cannot confirm oxygen flow, and as a result there is an increase in anxiety and the patient calls the home (DME) provider with concerns. Oxyview also allows the home (DME) provider to trouble-shoot other equipment problems over the telephone which eliminates an on-site visit with the patient. More important, the Oxyview provides the patient with more assurance that they are receiving adequate and prescribed oxygen flow. The Oxyview cost less than a single service call.





The Ingen Technologies, Inc. logo is available at